Recordati Industria Chimica e Farmaceutica S.p.A. (REC.VI)

51.25

-1.35

(-2.57%)

At close: 3:30:45 PM GMT+2

Recordati SpA (RCDTF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Recordati SpA (RCDTF) reports robust financial performance with significant growth in rare diseases and strategic market expansions, despite facing some regional challenges.

GuruFocus.com 3 days ago

RICFY
RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

Consolidated net revenue of € 680.0 million in the first quarter of 2025, +11.9% or +7.2% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 270.2 million, +10.7%, margin on revenue of 39.7% Adjusted net income(2) of € 175.5 million, +7.2% Net income of € 125.0 million, +1.2% Free cash flow(4) of € 158.8 million, +€ 11.7 million vs prior yearNet debt(5) at € 2,020.8 million, just below 2.2x EBITDA pro-forma(6)Isturisa® granted expanded approval by the FDA for the trea

GlobeNewswire 4 days ago

RCDTF

RICFY
RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION Milan, 28th April 2025 – The Board of Directors of Recordati S.p.A. has reviewed and approved the plan for the 2025-2027 three-year period. Recordati will continue executing on its strategy focused on driving organic growth of its current product portfolio across both Specialty & Primary

GlobeNewswire 14 days ago

RCDTF

RICFY
3 European Stocks Estimated To Be Trading At Discounts Of Up To 40.1%

As European markets face heightened volatility due to escalating trade tensions, the pan-European STOXX Europe 600 Index recently ended lower, reflecting investor concerns over global economic growth. In this uncertain environment, identifying stocks that are trading at significant discounts can present potential opportunities for investors seeking value.

Simply Wall St. 25 days ago

ERIC

ERIXF

RCDTF
RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME ISTURISA® is a cortisol synthesis inhibitor that blocks the enzyme 11β-hydroxylase to help normalize hypercortisolemia in Cushing’s syndrome, a rare endocrine condition that can have significant impact on patients and their familiesThe expanded indication is supported by an extensive clinical development program Milan, Italy and Bridgewater, NJ,

GlobeNewswire 26 days ago

RCDTF

RICFY
3 European Stocks Estimated To Be Undervalued In March 2025

As European markets navigate a complex landscape of mixed inflation data and economic contractions in major economies like Germany and France, the pan-European STOXX Europe 600 Index has shown resilience by posting its longest streak of weekly gains since August 2012. Against this backdrop, identifying stocks that may be undervalued becomes particularly pertinent for investors seeking opportunities amidst uncertainty.

Simply Wall St. 2 months ago

RCDTF

RICFY

SFRGF
RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4%PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS Consolidated net revenue of € 2,341.6 million for FY 2024, +12.4% or +9.2% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 865.8 million, +12.5%, revenue margin of 37.0% Adjusted net income(2) of € 568.9 million, +8.4% Net income of € 416.5 million, +7.0% Free cash flow(4) at € 535.1 million, +

GlobeNewswire 2 months ago

RCDTF

RICFY
3 Companies That May Be Trading Below Their Estimated Value

As global markets navigate the evolving economic landscape, U.S. stocks have been marching toward record highs, buoyed by optimism around potential trade deals and AI-related developments. Despite these gains, growth stocks have outperformed value shares, highlighting opportunities for investors to explore companies that may be trading below their estimated value. Identifying undervalued stocks often involves assessing a company's fundamentals and market position relative to current economic...

Simply Wall St. 3 months ago

RCDTF

RICFY
Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Recordati SpA (RICFY) reports a 12% revenue increase and confirms full-year targets despite challenges in Turkey and the US market.

GuruFocus.com 5 months ago

RICFY

SNY
RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

Consolidated net revenue of € 1,743.1 million in the first nine months, +12.0% or +9.3% on a like-for-like basis(3) and at constant exchange rates (CER)EBITDA(1) of € 665.7 million, +11.8%, revenue margin of 38.2% Adjusted net income(2) of € 445.4 million, +9.5% Net income of € 338.4 million, +11.1% Free cash flow(4) at € 434.3 million, +€ 42.5 million vs prior yearNet debt(5) at € 1,317.3 million, just below 1.6x EBITDAFinancial targets for FY 2024 confirmed, excluding any potential contributio

GlobeNewswire 5 months ago

RCDTF

RICFY
Recordati SpA (RICFY) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Recordati SpA (RICFY) reports a 30.5% increase in net revenue and upwardly adjusts its full-year financial targets, showcasing robust performance and strategic progress.

GuruFocus.com 6 months ago

RICFY
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati

On Friday, Italian pharma company Recordati S.p.A agreed to acquire the global rights to Enjaymo (sutimlimab) from Sanofi SA (NASDAQ:SNY) for $825 million as an upfront payment and additional commercial milestone payments of up to $250 million. Enjaymo, a humanized monoclonal antibody, is the only approved targeted product for cold agglutinin disease (CAD), a rare autoimmune disorder characterized by the premature destruction of red blood cells (hemolysis). Also Read: FDA Approves Regeneron/Sano

Benzinga 7 months ago

SNY

RICFY
Sanofi’s rare disease drug finds yet another home

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.

BioPharma Dive 7 months ago

SNY

RICFY
Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo

The strategic move is set to enhance Recordati's rare diseases franchise.

Pharmaceutical Technology 7 months ago

RICFY

SNY
RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi to acquire the global rights to Enjaymo® (sutimlimab), a biologic which is the only approved targeted product for the treatment of cold agglutinin disease (CAD), a rare B-cell lymphoproliferative disorder. Enjaymo® (sutimlimab) is a humanized monoclonal antibody indicated for the treatment of hemolysis in adults with CAD. In 2022, it was granted approval by the U.S. Food and Drug Administration (FDA), the European Commi

GlobeNewswire 7 months ago

RCDTF

RICFY

Performance Overview

Return	REC.VI	FTSE MIB Index (FTSEMIB.MI)
YTD	+0.89%	+16.78%
1-Year	+3.13%	+15.19%
3-Year	+38.41%	+69.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TARIFFS LATEST

Recordati Industria Chimica e Farmaceutica S.p.A. (REC.VI)

Recordati SpA (RCDTF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

RECORDATI: STRONG MOMENTUM OF THE GROUP CONTINUES INTO THE FIRST QUARTER OF 2025 REVENUE +11.9%, EBITDA(1) +10.7%, ADJUSTED NET INCOME(2) +7.2%

RECORDATI: 2025-2027 THREE-YEAR PLAN APPROVED FY 2027 TARGETS OF REVENUE BETWEEN € 3,000 AND € 3,200 MILLION; EBITDA(1) BETWEEN € 1,140 AND € 1,225 MILLION; ADJUSTED NET INCOME(2) BETWEEN € 770 AND € 820 MILLION

3 European Stocks Estimated To Be Trading At Discounts Of Up To 40.1%

RECORDATI: FDA GRANTS ISTURISA® (OSILODROSTAT) EXPANDED INDICATION FOR THE TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME

3 European Stocks Estimated To Be Undervalued In March 2025

RECORDATI: PRELIMINARY RESULTS FOR FULL YEAR 2024 REVENUE +12.4%, EBITDA(1) +12.5%, ADJUSTED NET INCOME(2) +8.4% PEAK YEAR SALES TARGETS RAISED FOR KEY RARE DISEASES PRODUCTS

3 Companies That May Be Trading Below Their Estimated Value

Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

Recordati SpA (RICFY) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...

Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati

Sanofi’s rare disease drug finds yet another home

Recordati to acquire worldwide rights to Sanofi’s antibody Enjaymo

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Performance Overview